AdAlta CEO Sam Cobb recently spoke to Danielle Doporto from Proactive Investors Australia in their Sydney studio. Sam gave an overview of AdAlta’s i-body platform technology and and it’s unique ability to reach difficult to access targets. Sam also demonstrated the market potential of AdAlta’s lead program, AD-214, for the treatment of the lung condition, Idiopathic Pulmonary Fibrosis, where currently available therapeutics generate yearly sales of US$1.5-2b.
AdAlta is one of the presenting companies at the Proactive Investors CEO Sessions to be held in Sydney on February 18 and Melbourne on February 19.
If you would like to receive further updates from AdAlta, including upcoming investor events, subscribe here.